Stay informed on the latest Truth Social posts from Donald Trump (@realDonaldTrump) without the doomscrolling. Consider it a public service for your mental health. (Why?)
Filtering by entity: Medicaid | Clear Filter
Summary:A letter from The White House, signed by Donald J. Trump and dated July 31, 2025, addresses AbbVie and other drug manufacturers, stating an Executive Order from May 12, 2025, aims to implement Most-Favored-Nation (MFN) drug pricing for American patients, demanding that US drug prices match those in other developed nations. The letter outlines specific demands for drug manufacturers, including extending MFN pricing to Medicaid, guaranteeing it for newly-launched drugs, repatriating foreign revenues, and participating in direct purchasing models, with a deadline for compliance by September 29, 2025, and a warning of further action if compliance is not met.
Sentiment:Directive
Key Claims:
- An Executive Order was signed on May 12, 2025, to deliver Most-Favored-Nation (MFN) prescription drug pricing to American patients.
- American brand name drug prices are up to three times higher than elsewhere, a result of 'global freeloading'.
- The Administration rejects policy changes that would result in 'billions of dollars in handouts to industry'.
- AbbVie and other drug manufacturers are called to extend MFN pricing to Medicaid for existing drugs.
- Drug manufacturers must guarantee MFN pricing for newly-launched drugs to Medicare, Medicaid, and commercial payers.
- Increased revenues generated abroad must be repatriated to lower drug prices for American patients and taxpayers.
- Drug manufacturers should provide for Direct Purchasing at MFN pricing via Direct-to-Consumer (DTC) and/or Direct-to-Business (DTB) models.
- The Administration will 'deploy every tool in our arsenal' if drug manufacturers do not comply with the demands.
- Binding commitments to meet these goals are expected by September 29, 2025.
Potential Market Impact (S&P 500):8/10
Potential Geopolitical Risk:0/10
Potential Global Cross-Asset Impact:7/10
Summary:A letter from the White House, signed by Donald Trump, addresses Boehringer Ingelheim and other pharmaceutical manufacturers, demanding they lower prescription drug prices for American patients to Most-Favored-Nation (MFN) levels and repatriate revenues from foreign markets, warning of further action if compliance is not met by September 29, 2025.
Sentiment:Directive
Key Claims:
- American patients pay up to three times more for prescription drugs than those in other developed nations due to 'global freeloading'.
- An Executive Order, 'Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,' was signed on May 12, 2025.
- Pharmaceutical manufacturers are called upon to extend MFN pricing to Medicaid for all existing drugs and to Medicare, Medicaid, and commercial payers for newly-launched drugs.
- Manufacturers are required to return increased revenues earned abroad to American patients and taxpayers.
- Manufacturers are urged to participate in Direct-to-Consumer and/or Direct-to-Business models for MFN pricing.
- The Administration will deploy 'every tool in our arsenal' if manufacturers do not comply.
- Binding commitments are expected from manufacturers by September 29, 2025.
- Secretary Kennedy and Administrator Oz are part of the implementation team for these policies.
Potential Market Impact (S&P 500):7/10
Potential Geopolitical Risk:0/10
Potential Global Cross-Asset Impact:7/10
Summary:The post consists of a letter from Donald Trump, dated July 31, 2025, addressed to Christopher Boerner of Bristol Myers Squibb, outlining demands for pharmaceutical companies to lower drug prices for American patients. The letter states that an Executive Order was signed on May 12, 2025, to ensure Americans pay the same drug prices as other developed nations, asserting that U.S. prices are currently up to three times higher due to other nations 'freeloading' on American innovation. It demands specific actions within 60 days, including extending Most-Favored-Nation (MFN) pricing to Medicaid and new drugs, repatriating increased revenues from abroad to lower U.S. prices, and providing for direct purchasing at MFN pricing. The letter indicates that if these demands are not met by September 29, 2025, the Administration will use 'every tool' to protect American families from 'abusive drug pricing practices,' with Secretary Kennedy and Administrator Oz prepared for implementation.
Sentiment:Directive
Key Claims:
- An Executive Order, 'Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,' was signed on May 12, 2025.
- The Executive Order aims to stop 'global freeloading' and guarantee Americans pay the same drug prices as other developed nations.
- Brand name drug prices in the United States are up to three times higher than elsewhere.
- This situation is an 'unacceptable burden on hardworking American families.'
- The Administration rejects proposals that result in 'handouts to industry.'
- Drug manufacturers must provide immediate relief from 'vastly inflated drug prices.'
- European and other developed nations are 'freeloading' off American innovation.
- Bristol Myers Squibb and all drug manufacturers are called to take specific actions within 60 days.
- MFN pricing must be extended to Medicaid for existing drugs.
- MFN pricing must be guaranteed for newly-launched drugs for Medicare, Medicaid, and commercial payers.
- Increased revenues from abroad must be returned to American patients and taxpayers.
- Direct Purchasing at MFN Pricing through DTC and/or DTB models must be provided.
- Secretary Kennedy and Administrator Oz are ready to implement these terms.
- If manufacturers refuse to comply, the Administration will deploy 'every tool' to protect American families from 'abusive drug pricing practices.'
- Americans are demanding lower drug prices.
- Binding commitments are expected by September 29, 2025.
Potential Market Impact (S&P 500):7/10
Potential Geopolitical Risk:0/10
Potential Global Cross-Asset Impact:6/10
Summary:A White House letter from July 31, 2025, addresses Novartis regarding an Executive Order from May 12, 2025, to implement Most-Favored-Nation (MFN) prescription drug pricing for American patients. The letter states that U.S. drug prices are up to three times higher than in other developed nations due to global freeloading and directs Novartis and other manufacturers to take specific actions within 60 days, including extending MFN pricing to Medicaid, guaranteeing MFN pricing for newly-launched drugs across all payers, returning increased revenues from abroad, and allowing direct purchasing at MFN rates. It warns that if manufacturers do not cooperate, the administration will deploy every tool to protect American families from abusive pricing, demanding binding commitments by September 29, 2025.
Sentiment:Directive
Key Claims:
- An Executive Order was signed on May 12, 2025, to establish Most-Favored-Nation (MFN) prescription drug pricing for American patients.
- Brand name drug prices in the United States are up to three times higher than in other developed nations due to global freeloading.
- Drug manufacturers, including Novartis, are directed to implement specific actions within 60 days.
- These actions include extending MFN pricing to Medicaid, guaranteeing MFN pricing for newly-launched drugs across all payers, repatriating increased revenues from abroad to American patients, and enabling direct purchasing at MFN rates.
- The administration will deploy "every tool" to combat abusive drug pricing if cooperation is not met.
- Binding commitments for these goals are required by September 29, 2025.
Potential Market Impact (S&P 500):8/10
Potential Geopolitical Risk:2/10
Potential Global Cross-Asset Impact:7/10
Summary:The post is a letter from the White House, dated July 31, 2025, to Gilead Sciences, Inc., demanding that the company and all drug manufacturers adopt 'Most-Favored-Nation' (MFN) drug pricing for American patients, extending it to Medicaid, new drugs, and direct purchasing, and repatriating revenues from abroad to lower U.S. drug prices, or face consequences from the Administration.
Sentiment:Directive
Key Claims:
- An Executive Order was signed on May 12, 2025, to ensure Americans pay the same drug prices as other developed nations.
- Brand name drug prices in the U.S. are up to three times higher than elsewhere for identical medicines.
- Current proposals from the industry involve 'shifting blame' and 'handouts.'
- Drug manufacturers must commit to providing immediate relief from inflated drug prices.
- Gilead Sciences, Inc., and all manufacturers are called upon to extend MFN pricing to existing Medicaid drugs.
- Manufacturers must guarantee MFN pricing for newly-launched drugs for Medicare, Medicaid, and commercial payers.
- Increased revenues from abroad must be repatriated to lower U.S. drug prices.
- Manufacturers should participate in direct-to-consumer/business distribution models for MFN pricing.
- Secretary Kennedy and Administrator Oz are ready to implement these terms.
- The Administration will deploy 'every tool in our arsenal' if drug manufacturers refuse to comply.
- Other nations have been 'freeloading' on U.S. innovation.
- Binding commitments are expected by September 29, 2025.
Potential Market Impact (S&P 500):7/10
Potential Geopolitical Risk:0/10
Potential Global Cross-Asset Impact:7/10
Summary:The post presents a letter from The White House, signed by Donald Trump, addressed to EMD Serono, demanding that pharmaceutical manufacturers implement "Most-Favored-Nation" drug pricing for American patients by September 29, 2025, to significantly lower prescription drug costs and end perceived "global freeloading."
Sentiment:Directive
Key Claims:
- An Executive Order titled "Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients" was signed on May 12, 2025, to ensure Americans pay the same drug prices as other developed nations.
- Brand name drug prices in the United States are up to three times higher than elsewhere.
- Pharmaceutical companies are called upon to extend Most-Favored-Nation (MFN) pricing to Medicaid for existing drugs.
- Pharmaceutical companies are called upon to guarantee MFN pricing for newly-launched drugs to Medicare, Medicaid, and commercial payers.
- Increased revenues earned abroad by manufacturers must be repatriated to lower drug prices for American patients and taxpayers.
- Manufacturers must provide for direct purchasing at MFN pricing through Direct-to-Consumer (DTC) and/or Direct-to-Business (DTB) models.
- The Administration will deploy every tool in its arsenal to protect American families if manufacturers refuse to comply with demands.
- Binding commitments to these goals are expected by September 29, 2025.
Potential Market Impact (S&P 500):7/10
Potential Geopolitical Risk:1/10
Potential Global Cross-Asset Impact:7/10
Summary:A letter from The White House, dated July 31, 2025, to Pfizer CEO Albert Bourla, outlines an Executive Order signed on May 12, 2025, aimed at ending high drug prices in the United States by mandating Most-Favored-Nation pricing for all drugs for American patients, and warns of consequences if drug manufacturers do not comply within 60 days.
Sentiment:Authoritative Directive
Key Claims:
- An Executive Order was signed on May 12, 2025, to implement Most-Favored-Nation (MFN) drug pricing for American patients.
- American drug prices are up to three times higher than in other developed nations due to 'global freeloading'.
- The Administration demands Pfizer and all drug manufacturers extend MFN pricing to Medicaid patients for existing drugs.
- The Administration demands Pfizer and all drug manufacturers guarantee MFN pricing for newly-launched drugs for all payers.
- The Administration demands increased revenues from abroad be repatriated to lower US drug prices.
- The Administration demands participation in direct purchasing models at MFN pricing.
- Non-compliance will result in the deployment of 'every tool in our arsenal' to protect American families.
- Binding commitments are expected by September 29, 2025.
Potential Market Impact (S&P 500):7/10
Potential Geopolitical Risk:0/10
Potential Global Cross-Asset Impact:5/10
Summary:The White House, on July 31, 2025, sent a letter to Novo Nordisk, outlining an Executive Order signed on May 12, 2025, that mandates drug manufacturers adopt Most-Favored-Nation (MFN) pricing for American patients, including for existing drugs via Medicaid and for new drugs for all payers. The letter claims that American patients currently pay up to three times more for brand-name drugs due to global freeloading and demands that increased revenues from higher prices charged abroad be repatriated to benefit American patients and taxpayers. It instructs manufacturers to implement direct purchasing at MFN pricing and warns that non-compliance by September 29, 2025, will result in the deployment of every available tool.
Sentiment:Directive
Key Claims:
- An Executive Order, 'Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,' was signed on May 12, 2025.
- Brand name drug prices in the United States are up to three times higher than in other developed nations due to 'global freeloading.'
- Drug manufacturers must extend Most-Favored-Nation (MFN) pricing to Medicaid for their full portfolio of existing drugs.
- Drug manufacturers must guarantee MFN pricing for newly-launched drugs to Medicare, Medicaid, and commercial payers.
- Increased revenues obtained abroad must be repatriated to lower drug prices for American patients and taxpayers.
- Manufacturers must provide for direct purchasing at MFN pricing through Direct-to-Consumer (DTC) and/or Direct-to-Business (DTB) distribution models for high-volume, high-rebate prescription drugs.
- Refusal to comply will result in the deployment of 'every tool in our arsenal to protect American families from continued abusive drug pricing practices.'
- Binding commitments to achieve these goals are required by September 29, 2025.
- Secretary Kennedy and Administrator Oz are part of the team ready to implement these terms.
Potential Market Impact (S&P 500):7/10
Potential Geopolitical Risk:1/10
Potential Global Cross-Asset Impact:6/10
Summary:The White House, under Donald Trump, has issued a directive to AstraZeneca and all drug manufacturers to implement Most-Favored-Nation (MFN) drug pricing for American patients, aiming to stop other nations from "freeloading" on American innovation and to lower prescription drug costs significantly by September 29, 2025.
Sentiment:Directive/Demanding
Key Claims:
- Americans currently pay up to three times more for identical prescription drugs than patients in other developed nations.
- Other nations are "freeloading" on American innovation in drug development.
- An Executive Order on "Most-Favored-Nation Prescription Drug Pricing" was signed on May 12, 2025.
- Drug manufacturers are called upon to extend MFN pricing to Medicaid, guarantee MFN pricing for newly-launched drugs, return increased revenues from abroad to American patients, and offer direct purchasing at MFN prices.
- The Administration is prepared to use every tool to protect Americans from abusive drug pricing practices if cooperation is not met.
- Binding commitments for these goals are expected by September 29, 2025.
Potential Market Impact (S&P 500):8/10
Potential Geopolitical Risk:0/10
Potential Global Cross-Asset Impact:7/10
Summary:A letter from the White House dated July 31, 2025, sent to Amgen, demands that drug manufacturers implement actions within 60 days, by September 29, 2025, to lower prescription drug prices for American patients to Most-Favored-Nation rates. The letter asserts that the US currently pays significantly more for brand name drugs than other developed nations due to 'global freeloading' and highlights an Executive Order signed on May 12, 2025, aimed at addressing this disparity.
Sentiment:Directive
Key Claims:
- An Executive Order titled 'Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients' was signed on May 12, 2025.
- Brand name drug prices in the United States are up to three times higher than elsewhere, attributed to 'global freeloading' and an 'unacceptable burden' on American families.
- Amgen and all manufacturers are called upon to implement specific actions within 60 days to address inflated drug prices.
- Required actions include extending Most-Favored-Nation (MFN) pricing to Medicaid, guaranteeing MFN pricing for newly-launched drugs, returning increased revenues from abroad to American patients and taxpayers, and providing for direct purchasing at MFN pricing.
- The administration is prepared to deploy 'every tool in our arsenal' to protect American families from 'abusive drug pricing practices' if manufacturers do not comply.
- The deadline for achieving these goals is September 29, 2025.
Potential Market Impact (S&P 500):8/10
Potential Geopolitical Risk:2/10
Potential Global Cross-Asset Impact:7/10
« Previous
Page 1 of 1
Next »